Endonovo Therapeutics Announces Effective Date of Previously Announced Reverse Split of Common Stock
December 19, 2019 18:24 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today that its previously announced 1-for-1,000 reverse split of...
Endonovo Therapeutics Reports Third Quarter 2019 Results
November 19, 2019 16:35 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today its financial results for the quarter ended September 30,...
Endonovo Therapeutics Enters into $10 million Common Stock Purchase Agreement with Azure Capital
January 03, 2019 11:10 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic...
Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
December 18, 2018 09:25 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies...
Endonovo Expands SofPulse Commercialization
December 13, 2018 09:20 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies,...
Endonovo Therapeutics Provides Update on Liver Study
October 22, 2018 10:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies,...